BACKGROUND: Emerging evidence suggests that the biology of sporadic colorectal neoplasia may differ between the proximal and distal colon. Whether such a difference exists in colitis-associated colorectal neoplasia is unknown. OBJECTIVE: To compare the rate of progression to advanced neoplasia (AN) between proximal and distal dysplasia in patients with ulcerative colitis (UC). DESIGN: Retrospective cohort study. SETTING: Tertiary medical center. PATIENTS: From an institutional database of more than 700 patients with UC who underwent 2 or more surveillance colonoscopies between 1994 and 2006, we identified patients with extensive UC and low-grade dysplasia (LGD). Neoplasia proximal to the splenic flexure was considered proximal. MAIN OUTCOME MEASUREMENT: Progression to AN, defined as high-grade dysplasia (HGD) or colorectal cancer (CRC). RESULTS: Among 121 patients with LGD, all 7 who progressed to CRC and 6 of 8 who progressed to HGD had distal LGD initially. Subjects with distal LGD had a significantly shorter time to progression than those with proximal LGD (P = .019); 5-year AN-free survivals for distal and proximal LGD were 75 ± 7% and 95 ± 3%, respectively (hazard ratio [HR] 5.0; 95% CI, 1.1-22.0). Additionally, flat LGD was significantly more likely to progress than raised LGD on univariate testing (HR 3.6; 95% CI, 1.3-10.1). Neither morphology nor sidedness remained significant in multivariable testing, although there was little change in the HRs (HR 2.4; 95% CI, 0.8-7.1 for morphology; HR 3.5; 95% CI, 0.7-16.8 for sidedness) in proportional hazards modeling. LIMITATIONS: Nonrandomized, retrospective trial and low incidence of AN. CONCLUSIONS: In patients with long-standing, extensive UC, distal LGD is more common and progresses more rapidly to AN than proximal LGD.
BACKGROUND: Emerging evidence suggests that the biology of sporadic colorectal neoplasia may differ between the proximal and distal colon. Whether such a difference exists in colitis-associated colorectal neoplasia is unknown. OBJECTIVE: To compare the rate of progression to advanced neoplasia (AN) between proximal and distal dysplasia in patients with ulcerative colitis (UC). DESIGN: Retrospective cohort study. SETTING: Tertiary medical center. PATIENTS: From an institutional database of more than 700 patients with UC who underwent 2 or more surveillance colonoscopies between 1994 and 2006, we identified patients with extensive UC and low-grade dysplasia (LGD). Neoplasia proximal to the splenic flexure was considered proximal. MAIN OUTCOME MEASUREMENT: Progression to AN, defined as high-grade dysplasia (HGD) or colorectal cancer (CRC). RESULTS: Among 121 patients with LGD, all 7 who progressed to CRC and 6 of 8 who progressed to HGD had distal LGD initially. Subjects with distal LGD had a significantly shorter time to progression than those with proximal LGD (P = .019); 5-year AN-free survivals for distal and proximal LGD were 75 ± 7% and 95 ± 3%, respectively (hazard ratio [HR] 5.0; 95% CI, 1.1-22.0). Additionally, flat LGD was significantly more likely to progress than raised LGD on univariate testing (HR 3.6; 95% CI, 1.3-10.1). Neither morphology nor sidedness remained significant in multivariable testing, although there was little change in the HRs (HR 2.4; 95% CI, 0.8-7.1 for morphology; HR 3.5; 95% CI, 0.7-16.8 for sidedness) in proportional hazards modeling. LIMITATIONS: Nonrandomized, retrospective trial and low incidence of AN. CONCLUSIONS: In patients with long-standing, extensive UC, distal LGD is more common and progresses more rapidly to AN than proximal LGD.
Authors: K K Gkouskou; M Ioannou; G A Pavlopoulos; K Georgila; A Siganou; G Nikolaidis; D C Kanellis; S Moore; K A Papadakis; D Kardassis; I Iliopoulos; F A McDyer; E Drakos; A G Eliopoulos Journal: Oncogene Date: 2015-08-17 Impact factor: 9.867
Authors: Triana Lobatón; Daniel Azuara; Francisco Rodríguez-Moranta; Carolina Loayza; Xavier Sanjuan; Javier de Oca; Ana Fernández-Robles; Jordi Guardiola; Gabriel Capellá Journal: World J Gastroenterol Date: 2014-08-14 Impact factor: 5.742
Authors: Mohammad Hadi Imanieh; Ali Goli; Mohammad Hossein Imanieh; Bita Geramizadeh Journal: Iran Red Crescent Med J Date: 2014-12-27 Impact factor: 0.611